Noetic Fund

What is Noetic Fund?

Noetic Fund is a venture capital firm that specializes in the early-stage investment cycle, focusing on seed, Series A, Series B, Series C, and Pre-IPO financing rounds.

Their headquarters are situated at 100 Broadview Ave Ste 300 in Toronto, Ontario, signaling their central operational base. Noetic Fund's investment thesis primarily targets the flourishing sectors of wellness, therapeutic, and psychedelic pharmaceuticals globally, emphasizing the development of novel treatments and therapies that optimize the human experience.

Like its namesake from the Greek "nosis" or "notikos," which signifies inner wisdom or direct understanding, Noetic Fund is heavily influenced by the principles of Noetic science—integrating scientific tools with subjective insight to delve into the full spectrum of human experiences.

Their mission is dedicated to the nurturing of scientific advancements in mental, emotional, and physiological health by supporting therapies that show significant promise in treating conditions related to the central nervous system, including mental health complexities and pain management.

With a commitment to innovation, safety, and accessibility, the firm endeavors to shape a better mental health landscape for present and future populations. Noetic Fund's portfolio spans a vast array of companies that are innovating in spaces like biotechnology, digital health, medical devices, and wellness. Companies they invest in are characterized by skilled teams with strong management experience and effective governance structures.

These investments include, but are not limited to, Apollo Neuroscience, Beckley Psytech, Bexson Biomedical, CaaMTech, COMPASS Pathways, and Cybin; each of these entities is creating cutting-edge solutions in their respective arenas. Noetic Fund's leadership is built on a foundation of diverse professionals with a breadth of expertise in finance, science, and legal matters, among other areas.

Collectively, this team guides Noetic Fund's strategic growth and supports the success of their investment endeavors.

What they say:

We invest in emerging and early-stage wellness, therapeutic and psychedelic pharmaceutical companies around the globe.